TY  - JOUR
AU  - Sannemann, Lena
AU  - Bartels, Claudia
AU  - Brosseron, Frederic
AU  - Buerger, Katharina
AU  - Fliessbach, Klaus
AU  - Freiesleben, Silka Dawn
AU  - Frommann, Ingo
AU  - Glanz, Wenzel
AU  - Heneka, Michael
AU  - Janowitz, Daniel
AU  - Kilimann, Ingo
AU  - Kleineidam, Luca
AU  - Lammerding, Dominik
AU  - Laske, Christoph
AU  - Munk, Matthias H J
AU  - Perneczky, Robert
AU  - Peters, Oliver
AU  - Priller, Josef
AU  - Rauchmann, Boris Stephan
AU  - Rostamzadeh, Ayda
AU  - Roy-Kluth, Nina
AU  - Schild, Ann-Katrin
AU  - Schneider, Anja
AU  - Schneider, Luisa-Sophie
AU  - Spottke, Annika
AU  - Spruth, Eike Jakob
AU  - Teipel, Stefan
AU  - Wagner, Michael
AU  - Wiltfang, Jens
AU  - Wolfsgruber, Steffen
AU  - Duezel, Emrah
AU  - Jessen, Frank
TI  - Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals.
JO  - Journal of Alzheimer's disease
VL  - 100
IS  - 1
SN  - 1387-2877
CY  - Amsterdam
PB  - IOS Press
M1  - DZNE-2024-00846
SP  - 193 - 205
PY  - 2024
AB  - The NIA-AA Research Framework on Alzheimer's disease (AD) proposes a transitional stage (stage 2) characterized by subtle cognitive decline, subjective cognitive decline (SCD) and mild neurobehavioral symptoms (NPS).To identify participant clusters based on stage 2 features and assess their association with amyloid positivity in cognitively unimpaired individuals.We included baseline data of N = 338 cognitively unimpaired participants from the DELCODE cohort with data on cerebrospinal fluid biomarkers for AD. Classification into the AD continuum (i.e., amyloid positivity, A+) was based on Aβ42/40 status. Neuropsychological test data were used to assess subtle objective cognitive dysfunction (OBJ), the subjective cognitive decline interview (SCD-I) was used to detect SCD, and the Neuropsychiatric Inventory Questionnaire (NPI-Q) was used to assess NPS. A two-step cluster analysis was carried out and differences in AD biomarkers between clusters were analyzed.We identified three distinct participant clusters based on presented symptoms. The highest rate of A+ participants (47.6
KW  - Humans
KW  - Male
KW  - Female
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - Amyloid beta-Peptides: metabolism
KW  - Aged
KW  - Cognitive Dysfunction: cerebrospinal fluid
KW  - Cognitive Dysfunction: psychology
KW  - Cognitive Dysfunction: diagnosis
KW  - Biomarkers: cerebrospinal fluid
KW  - Peptide Fragments: cerebrospinal fluid
KW  - Neuropsychological Tests
KW  - Alzheimer Disease: cerebrospinal fluid
KW  - Alzheimer Disease: psychology
KW  - Alzheimer Disease: diagnosis
KW  - Middle Aged
KW  - Cohort Studies
KW  - Aged, 80 and over
KW  - Cluster Analysis
KW  - Alzheimer’s disease (Other)
KW  - Alzheimer’s disease (Other)
KW  - Alzheimer’s disease continuum (Other)
KW  - NIA-AA stage 2 (Other)
KW  - amyloid (Other)
KW  - cerebrospinal fluid biomarkers (Other)
KW  - neuropsychiatric symptoms (Other)
KW  - preclinical Alzheimer’s disease (Other)
KW  - subjective cognitive decline (Other)
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - Peptide Fragments (NLM Chemicals)
KW  - amyloid beta-protein (1-42) (NLM Chemicals)
KW  - Alzheimer’s disease continuum (Other)
KW  - preclinical Alzheimer’s disease (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38848176
DO  - DOI:10.3233/JAD-231335
UR  - https://pub.dzne.de/record/270674
ER  -